Mutsuo Nakai
Okayama University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mutsuo Nakai.
Clinical Drug Investigation | 2003
Hirofumi Tsugeno; Mutsuo Nakai; Makoto Okamoto; Tadashi Yokoi; Shingo Takata; Norikazu Nishida; Kozo Ashida; Fumihiro Mitsunobu; Haruo Yuki; Yoshiro Tanizaki; Yasushi Shiratori
ObjectiveOsteoporosis is generally known to be one of the most serious adverse effects of long-term corticosteroid administration. Recently it was discovered that corticosteroid-induced osteoporosis occurs not only in trabecular bone but also in cortical bone, leading to a reduction in cortical bone strength. To ameliorate corticosteroid-induced bone injury, we administered etidronic acid plus alfacalcidol to five steroid-dependent asthmatics for 4 years and monitored therapeutic responses in trabecular bone and cortical bone using peripheral quantitative computed tomography (pQCT).Patients and interventionsThe five steroid-dependent asthmatic patients included two males and three females, with a mean age 68.2 years, taking a mean daily dose of oral prednisolone of 7 mg/day. Etidronic acid 200 mg/day was administered for 14 consecutive days every 4 months for 4 years, while alfacalcidol 0.5μg was administered daily for 4 years.Main outcome measures and resultsEvery 4 months, the number of vertebral fractures was assessed by lateral vertebral radiographs, and the total radial bone mineral density (BMD), trabecular BMD, cortical BMD, Relative Cortical Volume (RCV) and Strength Strain Index (SSI) were assessed by pQCT (Stratec XCT-960). At follow-up, no new fractures had occurred, the trabecular BMD was found to be slightly increased (from 117.2 mg/cm3 at baseline to 121.6 mg/cm3 after 48 months), and no significant decreases were observed in the total BMD, cortical BMD, RCV or SSI.ConclusionBased on these findings, etidronic acid plus alfacalcidol seems to be effective in preventing steroid-induced bone injury, not only in terms of trabecular and cortical BMD, but also in terms of cortical bone volume and strength, which may lead to a decrease in non-vertebral fractures. However, further investigation is required with a larger sample size and a longer administration period to confirm these findings.
European Respiratory Journal | 1999
Hirofumi Tsugeno; Mutsuo Nakai; Makoto Okamoto; Seishi Harada; Takashi Mifune; Fumihiro Mitsunobu; Kouzou Ashida; Yasuhiro Hosaki; Yoshiro Tanizaki; Takao Tsuji
Ann Rep Misasa Med Center, Okayama univ Med Sch | 2003
Fumihiro Mitsunobu; Kozo Ashida; Yasuhiro Hosaki; Hirofumi Tsugeno; Makoto Okamoto; Norikazu Nishida; Takuya Nagata; Shingo Takata; Tadashi Yokoi; Mutsuo Nakai; Yoshiro Tanizaki; Mitsune Tanimoto
岡大三朝分院研究報告 | 2002
Kozo Ashida; Fumihiro Mitsunobu; Yasuhiro Hosaki; Hirofumi Tsugeno; Makoto Okamoto; Shingo Takata; Tadashi Yokoi; Mutsuo Nakai; Hirofumi Makino; Yoshiro Tanizaki
Ann Rep Misasa Med Branch, Okayama univ Med Sch | 2002
Fumihiro Mitsunobu; Yasuhiro Hosaki; Kozo Ashida; Hirofumi Tsugeno; Makoto Okamoto; Norikazu Nishida; Shingo Takata; Tadashi Yokoi; Mutsuo Nakai; Yoshiro Tanizaki
岡大三朝分院研究報告 | 2001
Fumihiro Mitsunobu; Takashi Mifune; Kozo Ashida; Yasuhiro Hosaki; Hirofumi Tsugeno; Makoto Okamoto; Seishi Harada; Mutsuo Nakai; Yoshiro Tanizaki
岡大三朝分院研究報告 | 1999
Fumihiro Mitsunobu; Takashi Mifune; Kozo Ashida; Yasuhiro Hosaki; Hirofumi Tsugeno; Makoto Okamoto; Seishi Harada; Mutsuo Nakai; Yoshiro Tanizaki
岡大三朝分院研究報告 | 1997
Fumihiro Mitsunobu; Kozo Ashida; Takashi Mifune; Yasuhiro Hosaki; Hirofumi Tsugeno; Makoto Okamoto; Naofumi Iwagaki; Kazuhiko Yamamoto; Yoshiro Tanizaki; Mutsuo Nakai; Tsuneo Akiyama; Harumi Hasegawa
岡大三朝分院研究報告 | 1997
Yoshiro Tanizaki; Fumihiro Mitsunobu; Kozo Ashida; Takashi Mifune; Yasuhiro Hosaki; Hirofumi Tsugeno; Makoto Okamoto; Naofumi Iwagaki; Kazuhiko Yamamoto; Mutsuo Nakai; Tsuneo Akiyama
岡大三朝分院研究報告 | 1995
Mutsuo Nakai; Tsuneo Akiyama; Yoshiyasu Nakagiri; Yasuaki Kobayashi